1. A novel intrasaccular aneurysm device with high complete occlusion rate: initial results in a rabbit model.
- Author
-
Zoppo, Christopher T., Kolstad, Josephine W., King, Robert M., Wolfe, Thomas, Kraitem, Afif, Vardar, Zeynep, Badruddin, Aamir, Pereira, Edgard, Guerrero, Boris Pabón, Rosqueta, Arturo S., Ughi, Giovanni J., Gounis, Matthew J., Zaidat, Osama O., and Anagnostakou, Vania
- Subjects
INTRACRANIAL aneurysm surgery ,INTRACRANIAL aneurysms ,RESEARCH funding ,OPTICAL coherence tomography ,BLOOD vessel prosthesis ,SURGICAL stents ,ENDOVASCULAR surgery ,TREATMENT effectiveness ,DIGITAL subtraction angiography ,DESCRIPTIVE statistics ,ANIMAL experimentation ,PROTEOLYTIC enzymes ,COMPARATIVE studies ,POSTOPERATIVE period ,RABBITS ,EVALUATION - Abstract
Background Intrasaccular flow-disrupting devices are a safe and effective treatment strategy for intracranial aneurysms. We utilized high-frequency optical coherence tomography (HF-OCT) and digital subtraction angiography (DSA) to evaluate SEAL Arc, a new intrasaccular device, and compare the findings with the well-established Woven EndoBridge (WEB) device in an animal model of saccular aneurysms. Methods In a rabbit model, elastase-induced aneurysms were treated with SEAL Arc (n=11) devices. HF-OCT and DSA were performed after implant and repeated after 12 weeks. Device protrusion and malapposition were assessed at implant time and scored on a binary system. Aneurysm occlusion was assessed at 12 weeks with the WEB Occlusion Scale and dichotomized to complete (A and B) or incomplete (C and D) occlusion. The percentage of neointimal coverage after 12 weeks was quantified using HF-OCT. We compared these data to previously published historical controls treated with the gold-standard WEB device (n=24) in the same model. Results Aneurysm size and device placement were not significantly different between the two groups. Complete occlusion was demonstrated in 80% of the SEAL Arc devices, which compared favorably to the 21% of the aneurysms treated with WEB devices (P=0.002). Neointimal coverage across SEAL Arc devices was 86±15% compared with 49±27% for WEB (P=0.001). Protruding devices had significantly less neointimal coverage (P<0.001) as did incompletely occluded aneurysms (P<0.001). Histologically, all aneurysms treated with SEAL Arc devices were completely healed. Conclusion Complete early aneurysm occlusion was frequently observed in the SEAL Arc treated aneurysms, with significant neointimal coverage after 12 weeks. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF